Matthew Lowell - Alpha Teknova Chief Officer
| TKNO Stock | USD 7.19 0.14 1.91% |
Insider
Matthew Lowell is Chief Officer of Alpha Teknova
| Age | 54 |
| Address | 2451 Bert Dr., Hollister, CA, United States, 95023 |
| Phone | 831 637 1100 |
| Web | https://www.teknova.com |
Matthew Lowell Latest Insider Activity
Tracking and analyzing the buying and selling activities of Matthew Lowell against Alpha Teknova stock is an integral part of due diligence when investing in Alpha Teknova. Matthew Lowell insider activity provides valuable insight into whether Alpha Teknova is net buyers or sellers over its current business cycle. Note, Alpha Teknova insiders must abide by specific rules, including filing SEC forms every time they buy or sell Alpha Teknova'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Matthew Lowell over a year ago Purchase by Matthew Lowell of 10000 shares of Alpha Teknova |
Alpha Teknova Management Efficiency
The company has return on total asset (ROA) of (0.151) % which means that it has lost $0.151 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4151) %, meaning that it created substantial loss on money invested by shareholders. Alpha Teknova's management efficiency ratios could be used to measure how well Alpha Teknova manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to -0.31. In addition to that, Return On Capital Employed is likely to grow to -0.28. At this time, Alpha Teknova's Net Tangible Assets are very stable compared to the past year. As of the 25th of November 2024, Other Assets is likely to grow to about 217.3 K, while Total Assets are likely to drop about 125.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mitchell MBA | Petros Pharmaceuticals | 60 | |
| Patrick Bilbo | Organogenesis Holdings | 62 | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
| YatGai Au | Regencell Bioscience Holdings | 51 | |
| David Francisco | Organogenesis Holdings | 58 | |
| Aaron Perlitsh | Lifecore Biomedical | N/A | |
| Albert Bolles | Lifecore Biomedical | 66 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| Patricio Munoz | Procaps Group SA | 51 | |
| Wai Chung | Regencell Bioscience Holdings | 47 | |
| Melissa Angelini | Procaps Group SA | N/A | |
| Kurt Matheson | Organogenesis Holdings | N/A | |
| Damian Finio | Phibro Animal Health | 54 | |
| Michelle Chan | Regencell Bioscience Holdings | N/A | |
| Brian Grow | Organogenesis Holdings | 47 | |
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| Richard MD | Collegium Pharmaceutical | 64 | |
| Zorina Pitkin | Organogenesis Holdings | N/A | |
| Robert Weinstein | Petros Pharmaceuticals | 64 | |
| Jean Filippi | Phibro Animal Health | N/A | |
Management Performance
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.15 |
Alpha Teknova Leadership Team
Elected by the shareholders, the Alpha Teknova's board of directors comprises two types of representatives: Alpha Teknova inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpha. The board's role is to monitor Alpha Teknova's management team and ensure that shareholders' interests are well served. Alpha Teknova's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpha Teknova's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Damon JD, Chief Counsel | ||
| Matthew Lowell, Chief Officer | ||
| Ken Gelhaus, Chief Officer | ||
| Damon Terrill, Chief Counsel | ||
| Jennifer Henry, Senior Marketing | ||
| Stephen Gunstream, CEO President | ||
| Lisa McCann, Chief Officer |
Alpha Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpha Teknova a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.98) % | ||||
| Operating Margin | (0.53) % | ||||
| Current Valuation | 389.64 M | ||||
| Shares Outstanding | 53.3 M | ||||
| Shares Owned By Insiders | 9.32 % | ||||
| Shares Owned By Institutions | 82.28 % | ||||
| Number Of Shares Shorted | 288.2 K | ||||
| Price To Book | 4.48 X |
Pair Trading with Alpha Teknova
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alpha Teknova position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alpha Teknova will appreciate offsetting losses from the drop in the long position's value.Moving against Alpha Stock
| 0.89 | MTEM | Molecular Templates | PairCorr |
| 0.82 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.8 | TPST | Tempest Therapeutics | PairCorr |
| 0.79 | ME | 23Andme Holding | PairCorr |
| 0.78 | NKTX | Nkarta Inc | PairCorr |
The ability to find closely correlated positions to Alpha Teknova could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alpha Teknova when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alpha Teknova - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alpha Teknova to buy it.
The correlation of Alpha Teknova is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alpha Teknova moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alpha Teknova moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alpha Teknova can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alpha Teknova. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Alpha Stock, please use our How to Invest in Alpha Teknova guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alpha Teknova. If investors know Alpha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alpha Teknova listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.92) | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.17) | Return On Assets (0.15) | Return On Equity (0.42) |
The market value of Alpha Teknova is measured differently than its book value, which is the value of Alpha that is recorded on the company's balance sheet. Investors also form their own opinion of Alpha Teknova's value that differs from its market value or its book value, called intrinsic value, which is Alpha Teknova's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alpha Teknova's market value can be influenced by many factors that don't directly affect Alpha Teknova's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alpha Teknova's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alpha Teknova is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alpha Teknova's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.